Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Sun Sets On Copaxone, Teva Looks To New BD Horizons

This article was originally published in The Pink Sheet Daily

Executive Summary

Acting CEO Eyal Desheh said the company will be more open-minded about business development during the company’s fourth quarter financial call Feb. 6. Investors will have to wait to hear from incoming CEO Erez Vigodman for any new strategy to be articulated, however.

You may also be interested in...

Emerging Markets Earnings Roundup: Sanofi, Teva (Part 7)

Sanofi shows solid growth in emerging markets in the fourth quarter, including an impressive 35.1% gain in China. Teva in transition offers scant detail on emerging markets, but hints larger deals possible in 2014.

Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?

Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.

All Eyes On Pfizer For More Details On COVID-19 Vaccine Launch

Pfizer's COVID-19 vaccine is sure to dominate the third quarter results call, with everything from data to widescale distribution and the potential financial reward on the minds of investors and the public.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts